Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
Clinical trial NCT05310487 · COMPLETED
Trial details
- NCT number
- NCT05310487
- Sponsor
- Yangshengtang Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-30
- Primary completion
- 2023-10-03
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.